180 related articles for article (PubMed ID: 16681853)
1. HER 2/neu protein expression in colorectal cancer.
Schuell B; Gruenberger T; Scheithauer W; Zielinski Ch; Wrba F
BMC Cancer; 2006 May; 6():123. PubMed ID: 16681853
[TBL] [Abstract][Full Text] [Related]
2. Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country.
Shabbir A; Mirza T; Khalid AB; Qureshi MA; Asim SA
BMC Cancer; 2016 Nov; 16(1):855. PubMed ID: 27821098
[TBL] [Abstract][Full Text] [Related]
3. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?
Kavanagh DO; Chambers G; O'Grady L; Barry KM; Waldron RP; Bennani F; Eustace PW; Tobbia I
BMC Cancer; 2009 Jan; 9():1. PubMed ID: 19118499
[TBL] [Abstract][Full Text] [Related]
4. Clinical role of HER-2/neu expression in colorectal cancer.
Pappas A; Lagoudianakis E; Seretis C; Tsiambas E; Koronakis N; Toutouzas K; Katergiannakis V; Manouras A
J BUON; 2013; 18(1):98-104. PubMed ID: 23613394
[TBL] [Abstract][Full Text] [Related]
5. Comparative analysis of c-erbB-2 (HER-2/neu) in squamous cell carcinoma of the tongue: does over-expression exist? And what is its correlation with traditional diagnostic parameters?
Angiero F; Sordo RD; Dessy E; Rossi E; Berenzi A; Stefani M; Sidoni A
J Oral Pathol Med; 2008 Mar; 37(3):145-50. PubMed ID: 18251938
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer.
Rossi HA; Liu Q; Banner B; Hsieh CC; Savas L; Savarese D
Cancer J; 2002; 8(3):268-75. PubMed ID: 12074327
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.
Park DI; Kang MS; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Han WK; Kim H; Ryu SH; Sepulveda AR
Int J Colorectal Dis; 2007 May; 22(5):491-7. PubMed ID: 16947041
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas.
Kountourakis P; Pavlakis K; Psyrri A; Rontogianni D; Xiros N; Patsouris E; Pectasides D; Economopoulos T
Cancer J; 2006; 12(3):229-36. PubMed ID: 16803682
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical determination of HER-2/neu in malignant melanoma.
Potti A; Hille R; Koch M
Anticancer Res; 2003; 23(5A):4067-9. PubMed ID: 14666720
[TBL] [Abstract][Full Text] [Related]
10. Her-2/neu over-expression correlates with more advanced disease in Iranian colorectal cancer patients.
Tavangar SM; Shariftabrizi A; Soroush AR
Med Sci Monit; 2005 Mar; 11(3):CR123-6. PubMed ID: 15735564
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma.
Potti A; Ganti AK; Koch M; Levitt R; Mehdi SA
Leuk Lymphoma; 2002 Dec; 43(12):2427-30. PubMed ID: 12613538
[TBL] [Abstract][Full Text] [Related]
12. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.
Forseen SE; Potti A; Koka V; Koch M; Fraiman G; Levitt R
Anticancer Res; 2002; 22(3):1599-602. PubMed ID: 12168843
[TBL] [Abstract][Full Text] [Related]
13. The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters.
Essapen S; Thomas H; Green M; De Vries C; Cook MG; Marks C; Topham C; Modjtahedi H
Int J Oncol; 2004 Feb; 24(2):241-8. PubMed ID: 14719098
[TBL] [Abstract][Full Text] [Related]
14. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis.
Wu SW; Ma CC; Li WH
Diagn Pathol; 2015 Aug; 10():144. PubMed ID: 26276145
[TBL] [Abstract][Full Text] [Related]
15. Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia.
Potti A; Ganti AK; Koch M; Mehdi SA; Levitt R
Lung Cancer; 2001 Nov; 34(2):227-32. PubMed ID: 11679181
[TBL] [Abstract][Full Text] [Related]
16. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens MR
J Clin Pathol; 2005 Jun; 58(6):611-6. PubMed ID: 15917412
[TBL] [Abstract][Full Text] [Related]
17. Her-2/neu gene amplification and protein expression in primary male breast cancer.
Rudlowski C; Friedrichs N; Faridi A; Füzesi L; Moll R; Bastert G; Rath W; Büttner R
Breast Cancer Res Treat; 2004 Apr; 84(3):215-23. PubMed ID: 15026619
[TBL] [Abstract][Full Text] [Related]
18. Expression analyses of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients.
Beckmann MW; Niederacher D; Massenkeil G; Tutschek B; Beckmann A; Schenko G; Schnürch HG; Bender HG
Oncology; 1996; 53(6):441-7. PubMed ID: 8960138
[TBL] [Abstract][Full Text] [Related]
19. Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia.
Kamil M; Yusuf N; Khalid I; Islam R; Biswas M; Hashim H
Ceylon Med J; 2010 Mar; 55(1):9-13. PubMed ID: 20446534
[TBL] [Abstract][Full Text] [Related]
20. Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma.
Potti A; Ganti AK; Sholes K; Langness E; Koka V; Horvarth L; Koch M
Clin Cancer Res; 2003 Oct; 9(13):4872-6. PubMed ID: 14581360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
